The FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso for the treatment of non-small cell lung cancer.
The FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso for the treatment of non-small cell lung cancer.